EcoDrugPlus

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSNGAG00000002514
Gene Symbol: MAPK3
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSNGAG00000021076
Gene Symbol: MAPK8
3 Cross references
294 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSNGAG00000019965
Gene Symbol: MAPK9
3 Cross references
217 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSNGAG00000006894
Gene Symbol: MAP2K1
3 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSNGAG00000023259
Gene Symbol: MAP2K2
3 Cross references
261 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSNGAG00000021146
Gene Symbol: MAP3K1
3 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSNGAG00000021252
Gene Symbol: MAP3K10
3 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSNGAG00000005852
Gene Symbol: MAP3K11
3 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSNGAG00000017001
Gene Symbol: MAP3K12
3 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSNGAG00000017162
Gene Symbol: MAP3K13
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSNGAG00000000561
Gene Symbol: MAP3K5
3 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSNGAG00000012283
Gene Symbol: MAP3K8
2 Cross references
151 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).